Financial News

Date Title
08/11/22 National Cancer Center Hospital in Tokyo Upgrades to MRIdian® Linac for MRI-Guided Radiation Therapy and has treated its first patients
08/08/22 ViewRay Selects Denver for Headquarters
08/02/22 ViewRay Announces Second Quarter 2022 Results
08/02/22 ViewRay and Katie Couric Media Partner to Raise Awareness about MRIdian® MRI-Guided Radiation Therapy
07/29/22 Centre Oscar Lambret Selects ViewRay's MRIdian® MRI-Guided Radiation Therapy System
07/20/22 Miami Cancer Institute First in World to Deliver Adaptive MR-Guided Radiation Therapy with the MRIdian® A3i System
07/19/22 Saitama Medical University International Medical Center Selects MRIdian® MRI-Guided Radiation Therapy System
07/19/22 ViewRay Announces Conference Call for Second Quarter 2022 Financial Results to be Held After Market on August 2, 2022
06/09/22 VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
06/07/22 Shin-Matsudo Central General Hospital Select's ViewRay's MRIdian® MRI-Guided Radiation Therapy System to Expand Access to Precision Radiation Therapy
06/02/22 Henry Ford Health Becomes the First Center to Treat Patients with ViewRay's MRIdian A3i System
05/10/22 Clinical Value of MRIdian® MRI-Guided Radiation Therapy in the Treatment of Ultracentral/Central Lung Tumors Presented at ESTRO 2022
05/06/22 MRIdian Clinical and Research Experience Featured in Nearly 40 Abstracts at ESTRO 2022, the Leading European Radiation Oncology Meeting
05/05/22 ViewRay Announces First Quarter 2022 Results
05/05/22 ViewRay Named “Best Overall MedTech Company” in 2022 MedTech Breakthrough Awards Program
05/03/22 UCI Health Adopts ViewRay® MRIdian® MRI-Guided Radiation Therapy System
04/21/22 ViewRay Announces Conference Call for First Quarter 2022 Financial Results to be Held After Market on May 5, 2022
03/15/22 University Hospital Agostino Gemelli Treats its 1,000th Patient Using MRIdian® MRI-Guided Radiation Therapy
03/10/22 ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022
03/10/22 First Toxicity Results from SCIMITAR Prospective Phase II Trial Signal Favorable Toxicity Profile of Post-Prostatectomy Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer
03/09/22 ViewRay Enters into Cooperation Agreement with Hudson Executive Capital
03/03/22 Acibadem Group Purchases Second MRIdian® System for Acibadem Altunizade Hospital in Istanbul
02/24/22 ViewRay Announces Fourth Quarter and Full Year 2021 Results
02/15/22 Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
02/10/22 ViewRay® to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
02/10/22 ViewRay Announces Conference Call for Fourth Quarter and Full Year 2021 Financial Results to be Held After Market on February 24, 2022
02/09/22 University Hospital Halle (Saale) Selects ViewRay's MRIdian® System to Broaden Advanced Radiation Therapy Treatment Services
01/25/22 ViewRay® to Participate in the B. Riley Securities Oncology Conference
01/10/22 ViewRay Announces Preliminary Fourth Quarter and Full Year 2021 Results

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Financial Events
More events are coming soon.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select